NASDAQ : TTRX
Turn Therapeutics Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 10.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 319.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cost of Revenue | 1.61M | 496.95K | |||
| Gross Profit | -1.61M | -496.95K | |||
| Selling, General & Admin | 6.17M | 5.59M | 1.55M | 2.30M | 4.21M |
| Research & Development | 778.13K | 265.57K | 245.96K | 7.50K | |
| Operating Expenses | 6.95M | 5.86M | 1.80M | 2.31M | 4.21M |
| Operating Income | -8.56M | -6.36M | -1.80M | -2.31M | -4.21M |
| Interest Expense | -223.22K | -85.38K | |||
| Interest & Investment Income | 19.29K | 29.58K | 28.71K | 15.88K | 9.11K |
| Other Non Operating Income (Expenses) | 321.24K | 3.13M | |||
| Pretax Income | -8.45M | -3.19M | -1.77M | -2.29M | -4.29M |
| Income Tax Expense | 800.00 | ||||
| Net Income | -8.45M | -3.19M | -1.77M | -2.29M | -4.29M |
| Net Income to Common | -8.45M | -3.19M | -1.77M | -2.29M | -4.29M |
| Shares Outstanding (Basic) | 28.92M | 27.72M | 26.64M | 26.49M | |
| Shares Outstanding (Diluted) | 28.92M | 27.72M | 26.64M | 26.49M | |
| EPS (Basic) | -0.29 | -0.12 | -0.07 | -0.09 | |
| EPS (Diluted) | -0.29 | -0.12 | -0.07 | -0.09 | |
| EBITDA | -8.51M | -6.30M | -1.75M | -2.26M | -4.16M |
| D&A For EBITDA | 56.82K | 52.75K | 47.48K | 43.92K | 52.74K |
| EBIT | -8.56M | -6.36M | -1.80M | -2.31M | -4.21M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 10.29M | 5.08M | 872.60K | 1.18M | 2.10M |
| Cash & Short-Term Investments | 10.29M | 5.08M | 872.60K | 1.18M | 2.10M |
| Prepaid Expenses | 139.69K | 120.30K | 225.32K | 20.82K | 22.47K |
| Total Current Assets | 10.43M | 5.20M | 1.10M | 1.20M | 2.13M |
| Property, Plant & Equipment | 56.27K | 78.62K | 120.45K | 33.22K | 81.38K |
| Other Intangible Assets | 911.22K | 922.17K | 821.93K | 769.94K | 698.00K |
| Long-Term Deferred Charges | 5.56M | 5.96M | |||
| Other Long-Term Assets | 8.58K | 8.58K | 8.58K | 8.58K | 8.58K |
| Total Assets | 16.96M | 12.16M | 2.05M | 2.01M | 2.91M |
| Accounts Payable | 2.61M | 2.93M | 667.27K | 464.62K | 255.96K |
| Current Portion of Leases | 49.33K | 46.30K | 40.66K | 25.16K | 49.47K |
| Current Unearned Revenue | 1.42M | ||||
| Other Current Liabilities | 6.11M | 3.03M | |||
| Total Current Liabilities | 8.76M | 6.00M | 707.93K | 489.78K | 1.72M |
| Long-Term Leases | 8.71K | 34.08K | 80.38K | 34.20K | |
| Long-Term Unearned Revenue | 1.44M | 1.44M | 1.44M | 1.44M | |
| Total Liabilities | 16.27M | 7.48M | 2.23M | 1.93M | 1.76M |
| Common Stock | 2.98K | 2.94K | 2.68K | 1.32K | 1.32K |
| Additional Paid-In Capital | 29.89M | 28.14M | 19.02M | 17.51M | 18.37M |
| Retained Earnings | -29.21M | -22.39M | -19.20M | -17.43M | -17.22M |
| Comprehensive Income & Other | -1.07M | ||||
| Shareholders' Equity | 686.89K | 4.69M | -177.43K | 85.77K | 1.16M |
| Total Liabilities & Equity | 16.96M | 12.16M | 2.05M | 2.01M | 2.91M |
| Total Debt | 6.12M | 80.38K | 121.04K | 25.16K | 83.67K |
| Net Cash (Debt) | 4.17M | 5.00M | 751.56K | 1.16M | 2.02M |
| Net Cash Per Share | 0.14 | 0.18 | 0.03 | 0.04 | |
| Filing Date Shares Outstanding | 29.79M | 29.79M | 26.85M | 26.49M | |
| Total Common Shares Outstanding | 29.79M | 29.45M | 26.85M | 26.49M | |
| Working Capital | 1.66M | -806.98K | 389.99K | 712.04K | 401.44K |
| Book Value Per Share | 0.02 | 0.16 | -0.01 | 0.00 | |
| Tangible Book Value | -224.33K | 3.76M | -999.36K | -684.17K | 457.20K |
| Tangible Book Value Per Share | -0.01 | 0.13 | -0.04 | -0.03 | |
| Machinery | 13.04K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -8.45M | -3.19M | -1.77M | -2.29M | -4.29M |
| Depreciation & Amortization | 56.82K | 52.75K | 47.48K | 43.92K | 52.74K |
| Stock-Based Compensation | 995.53K | 669.25K | 352.83K | 640.26K | 1.88M |
| Other Operating Activities | 185.84K | -2.46M | 8.65K | 662.00 | 47.75K |
| Change in Accounts Payable | 1.59M | 2.26M | 202.65K | 208.66K | -302.95K |
| Change in Unearned Revenue | 19.43K | 1.42M | |||
| Change in Other Net Operating Assets | 64.33K | 105.03K | -204.50K | 1.65K | -14.24K |
| Operating Cash Flow | -4.32M | -2.56M | -1.36M | -1.38M | -1.21M |
| Sale (Purchase) of Intangibles | -139.26K | -152.99K | -99.47K | -44.31K | -17.69K |
| Investing Cash Flow | -139.26K | -152.99K | -99.47K | -44.31K | -17.69K |
| Issuance of Common Stock | 4.84M | 6.92M | 1.15M | 500.00K | 350.00K |
| Financing Cash Flow | 11.56M | 6.92M | 1.15M | 500.00K | 350.00K |
| Net Cash Flow | 7.10M | 4.20M | -308.40K | -921.99K | -874.40K |
| Levered Free Cash Flow | 4.17M | 1.74M | -824.22K | -2.01M | |
| Unlevered Free Cash Flow | 4.19M | 1.74M | -824.22K | -2.01M | |
| Change in Working Capital | 1.65M | 2.37M | -1.86K | 229.74K | 1.10M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 310.69M | 116.01M | |||
| Enterprise Value | 306.52M | 113.00M | |||
| Last Close Price | 10.43 | 3.94 | |||
| PB Ratio | 452.31 | 24.75 | |||
| P/TBV Ratio | 30.82 | ||||
| Debt / Equity Ratio | 8.91 | 0.02 | -0.68 | 0.29 | 0.07 |
| Net Debt / Equity Ratio | -6.07 | -1.07 | 4.24 | -13.48 | -1.75 |
| Net Debt / EBITDA Ratio | 0.49 | 0.79 | 0.43 | 0.51 | 0.49 |
| Quick Ratio | 1.17 | 0.85 | 1.23 | 2.41 | 1.22 |
| Current Ratio | 1.19 | 0.87 | 1.55 | 2.45 | 1.23 |
| Return on Equity (ROE) | -686.28% | -141.67% | -369.43% | ||
| Return on Assets (ROA) | -50.27% | -55.90% | -55.30% | -58.56% | |
| Return on Capital Employed (ROCE) | -104.50% | -103.20% | -134.00% | -151.50% | -353.90% |
| Earnings Yield | -2.80% | -2.75% | |||
| Buyback Yield / Dilution | -7.07% | -4.03% | -0.56% |